Special Infectious Diseases - HIV /AIDS   


Research Opportunities Children's HIV/AIDS Program is the leader in Chicago to provide patients with the opportunity to enroll in pediatric or adolescent HIV/AIDS clinical research studies sponsored by the National Institutes of Health. Children's HIV/AIDS Program offers patients access to the latest medication and treatment available. This research will continue to:
       * Advance the standards of HIV care significantly 
            * Improve the quality of life for HIV infected patients 
                   * Reduce new infection rates
Children's HIV/AIDS Program is one of the top rated pediatric HIV research sites in the country with more than 185 patients enrolled in government sponsored clinical trials.

In addition, Children’s HIV/AIDS Program participates in numerous pharmaceutical company’s clinical research studies that strive to improve medication alternatives for HIV patients. These studies afford our patients access to cutting-edge research and medications that are designed to improve their quality of life until effective vaccines and a cure are found.
Advanced Laboratories Children's HIV/AIDS Program has an on-site laboratory certified in various HIV tests from which we can obtain tests faster than any other institution in the Chicago area. Our lab has become one of the top rated pediatric HIV/AIDS labs in the country. In fact, the advanced on-site lab at Children's Memorial provides pediatric HIV testing for Cook County Hospital, the University of Chicago, Loyola University Medical Center, Lutheran General Hospital, Mt. Sinai Hospital, and other institutions. 

 


Safety and Effectiveness of Raltegravir (MK-0518) in Treatment-Experienced, HIV-Infected Children and Adolescents 
Interventions: Drug: Raltegravir (MK-0518)
Principal Investigator: Ellen Chadwick, MD and Ram Yogev, MD
Contact: Margaret A. Sanders, MPH
Phone: 773-880-3669
Email:

IRB Number: 2007-13231 (ClinicalTrials.gov identifier: NCT00485264)

Early Initiation of HAART Condition: HIV Infections
Interventions: Procedure: Early Initiation of Highly Active Anti-Retroviral Therapy; Standard Care
Principal Investigator: Robert Garofalo, MD, MPH and Ram Yogev, MD 
Contact: Margaret A. Sanders, MPH
Phone: 773-880-3669
Email:

IRB Number 2007-13264( ATN 061; ClinicalTrials.gov identifier: NCT00491556)
Vitamin D Reabsorption in Adolescents and Young Adults with HIV Infection 
Condition: HIV Infections
Interventions: Dietary Supplement: Vitamin D supplement; Other: Placebo
Principal Investigator: Robert Garofalo, MD, MPH and Ram Yogev, MD 
Contact: Margaret A. Sanders, MPH
Phone: 773-880-3669
Email:

IRB Number 2008-13311 (ATN 063; ClinicalTrials.gov identifier: NCT00490412)
Prenatal and Postnatal Studies of Interventions for Prevention of Mother-To-Child Transmission
Principal Investigator: Debbie Fonken-Cloutier, RN, BS
Phone:  773-880-3669 
Email: 
 
Clinical Trials.gov NCT00028145

Safety of and Immune Response to a Meningitis Vaccine in HIV Infected Children and Youth
Principal Investigator: Ram Yogev, MD
Contact: Margaret A. Sanders, MPH
Phone: 773-880-3669
Email:
 

IRB Number: 2007-13024 (ClinicalTrials.gov identifier:  NCT00459316)  

An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection
Principal Investigator: Ram Yogev, MD
Contact: Margaret A. Sanders, MPH
Phone: 773-880-3669
Email:

ClinicalTrials.gov Identifier: NCT00162227  

A Study of Intravenous Oseltamivir [Tamiflu] in Infants With Influenza  
Principal Investigator: Evan J. Anderson, MD

Phone:  773-880-4390
Email:

IRB Number:  2010-14056 (ClinicalTrials.gov Identifier:  NCT01053663)

An Observational Study to Assess Respiratory Syncytial Virus (RSV) Respiratory Events Among Premature Infants
Principal Investigator: Evan J. Anderson, MD
Phone:  773-880-4390
Email:

IRB Number: 2009-13992 (Clinical Trials.gov Identifier: NCT00983606)
Evaluation of Meningococcal Immune Response Among Children Who Previously Received MenACWY Conjugate Vaccine
Principal Investigator: Ram Yogev, MD
Contact: Margaret A. Sanders, MPH
Phone: 773-880-3669
Email:

IRB Number: 2010-14274 (ClinicalTrials.gov identifier:  NCT01148017)  

Accuracy of the Pima™ CD4 Test for Enumeration of CD4+ T-Cell Counts 
Principal Investigator: Ram Yogev, MD
Contact: Margaret A. Sanders, MPH
Phone: 773-880-3669
Email:

IRB Number: 2009-13993 (ClinicalTrials.gov identifier:  NCT00951795)

Pharmacokinetic Effects of New Antiretroviral Drugs on Children, Adolescents and Young Adults 
Principal Investigator: Ram Yogev, MD
Contact: Margaret A. Sanders, MPH
Phone: 773-880-3669
Email:

IRB Number: 2009-13980 (ClinicalTrials.gov identifier:  NCT00977756)

Safety and Effectiveness of Oral Alendronate Therapy on Bone Mineral Density in HIV-infected Children and Adolescents With Low Bone Mineral Density
Principal Investigator: Ram Yogev, MD
Contact: Margaret A. Sanders, MPH
Phone: 773-880-3669
Email:

IRB Number: 2009-13910 (ClinicalTrials.gov identifier:  NCT00921557)

Evaluating Strategies to Reduce Mother-to-Child Transmission of HIV Infection in Resource-Limited Countries (PROMISE)
Principal Investigator: Ram Yogev, MD
Contact: Margaret A. Sanders, MPH
Phone: 773-880-3669
Email:

IRB Number: 2009-13945 (ClinicalTrials.gov identifier:  NCT01061151)

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Viral Shedding of MEDI-559 in Healthy 1 to <24 Month-Old Children
Principal Investigator: Ram Yogev, MD
Contact: Margaret A. Sanders, MPH
Phone: 773-880-3669
Email:

IRB Number: 2009-13920 (ClinicalTrials.gov identifier:  NCT00767416)

Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women
Principal Investigator: Ram Yogev, MD
Contact: Margaret A. Sanders, MPH
Phone: 773-880-3669
Email:

IRB Number: 2009-13886 (ClinicalTrials.gov identifier:  NCT00604175)

Long-Term Outcomes in HIV-Infected Infants, Children, and Adolescents
Principal Investigator: Ram Yogev, MD
Contact: Margaret A. Sanders, MPH
Phone: 773-880-3669
Email:

IRB Number: 2009-13808 (ClinicalTrials.gov identifier:  NCT01061164)

Safety and Effectiveness of Atorvastatin in HIV Infected Children and Adolescents With Hyperlipidemia
Principal Investigator: Ram Yogev, MD
Contact: Margaret A. Sanders, MPH
Phone: 773-880-3669
Email:

IRB Number: 2009-13521 (ClinicalTrials.gov identifier:  NCT0063234)